EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

Davide Spica, Till Junker, Michael Dickenmann, Stefan Schaub, Jürg Steiger, Tanja Rüfli, Jörg Halter, Helmut Hopfer, Andreas Holbro, Patricia Hirt-Minkowski

Case Reports in Nephrology and Dialysis · 13.11.2019 · 9 (3) · 149-157

DOI: 10.1159/000503951 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Nephrology and Dialysis, online erschienen am 13.11.2019. Verfasst von Davide Spica und 9 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the effectiveness of daratumumab, a human IgGκ monoclonal antibody targeting CD38 on plasma cells, for therapy-refractory antibody-mediated rejection (AMR) due to blood group antibodies in a 59-year-old man who received a living ABO-incompatible kidney transplantation. Standard treatment options for AMR due to blood group antibodies including immunoadsorption, lymphocyte depletion with anti-human T-lymphocyte globulins, intravenous methylprednisolone pulses and eculizumab limited tissue injury, however failed to sufficiently suppress blood group antibody production. After administration of daratumumab as a rescue therapy, blood group antibody titers decreased and remained at low levels without further immunoadsorption and allowed kidney graft function to recover.

Schlagwörter

Stichwörter der Autor:innen

ABO-incompatible kidney transplantationAnti-rejection therapyAntibody-mediated rejectionDaratumumab

Autor:innen und Institutionen

  • Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
  • Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
  • Transplantation Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • HLA-Diagnostic and Immunogenetics, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
  • Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
  • Institute for Pathology, University Hospital Basel, Basel, Switzerland.

Zitieren

APA

Spica, D., Junker, T., Dickenmann, M., Schaub, S., Steiger, J., Rüfli, T., Halter, J., Hopfer, H., Holbro, A., & Hirt-Minkowski, P. (2019). Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Nephrology and Dialysis, 9(3), 149-157. https://doi.org/10.1159/000503951

Vancouver

Spica D, Junker T, Dickenmann M, Schaub S, Steiger J, Rüfli T, et al. Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Nephrology and Dialysis. 2019;9(3):149-157. doi:10.1159/000503951

BibTeX
@article{Spica2019,
  author = {Spica, Davide and Junker, Till and Dickenmann, Michael and Schaub, Stefan and Steiger, Jürg and Rüfli, Tanja and Halter, Jörg and Hopfer, Helmut and Holbro, Andreas and Hirt-Minkowski, Patricia},
  title = {Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation},
  journal = {Case Reports in Nephrology and Dialysis},
  year = {2019},
  volume = {9},
  number = {3},
  pages = {149--157},
  doi = {10.1159/000503951}
}
Kostenlos starten →